ABERDEEN, Scotland and SINGAPORE, 1 June 2015 – With the publication of a key article in The Journal of Biological Chemistry, TauRx Pharmaceuticals Ltd. continues to build a growing body of evidence supporting the rationale for tau aggregation inhibition in the treatment of neurodegenerative diseases such as Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD). This latest of six connected papers, five of them published in the past six months describes the robust scientific research programme behind the development of LMTXTM, the second‐generation tau aggregation inhibitor (TAI) currently in three large global Phase 3 clinical trials.
Read more here.
With the publication of a key article in The Journal of Biological Chemistry, TauRx continues to build a growing body of evidence supporting tau aggregation inhibition
